Annovis Q3 Loss Widens as R&D Hits $15.8M; DUET-AD Data Due March 2027
ANVS sits 53% above its 52-week low of $0.616.
Summary
Annovis reported a $9.5 million Q3 net loss on R&D of $15.8 million and $2.8 million of cash at September 30; the $21.0 million November offering is expected to carry it to DUET-AD topline data in March 2027.
Key Events · Earnings and Guidance · ANVS
-
Q3 Net Loss of $9.5 Million
Net loss was $9.5 million, or $0.22 per share, versus $7.3 million a year earlier; the nine-month loss reached $41.9 million.
-
R&D Spending More Than Doubles
R&D expense was $15.8 million for the quarter versus $6.3 million a year earlier, and $44.5 million for the nine months versus $16.5 million.
-
Cash of $2.8 Million at Quarter-End
Cash fell to $2.8 million from $19.5 million at December 31, 2025; the $21.0 million offering that closed November 6 is expected to fund operations through the DUET-AD 6-month readout.
-
DUET-AD Readout Set for March 2027
Last patient, last visit of the 6-month treatment period is scheduled for December 31, 2026, database lock February 8, 2027, and topline results in March 2027.
Analysis · ANVS · Life Sciences
Cash burn is the story this quarter: R&D spending more than doubled to $15.8 million from $6.3 million a year earlier, and the nine-month operating loss reached $49.4 million against a $2.8 million cash balance at September 30. That balance is survivable only because the $21.0 million offering closed November 6, and management says it funds operations through the 6-month DUET-AD readout in March 2027 — leaving the company financed to exactly one binary event, with no cushion past it. The warrant liability jumping to $12.5 million is a non-cash mark-to-market tied to the higher share price, not new dilution or cash owed. The stock's path now hinges on the December 31 last-patient visit, the February 8 database lock, and March 2027 topline.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANVS was trading at $0.94 on NYSE in the Life Sciences sector, with a market capitalization of approximately $39.5M. The 52-week trading range was $0.62 to $5.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.